Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%78 Earnings per Share (Diluted) is $0.32 as of Dec. 2025. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 101 Medical Distribution companies, Sinopharm Group Co ranks worse than 63.37% on this metric.
Sinopharm Group Co's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.17.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.32.
During the past 12 months, Sinopharm Group Co's average EPS without NRIGrowth Rate was -4.90% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -6.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -3.30% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 7.20% per year.
During the past 13 years, Sinopharm Group Co's highest 3-Year average EPS without NRI Growth Rate was 115.70% per year. The lowest was -6.40% per year. And the median was 17.10% per year.
Sinopharm Group Co (OTCPK:SHTDF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sinopharm Group Co Earnings per Share (Diluted) Related Terms
Sinopharm Group Co Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Earnings per Share (Diluted) Chart
SHTDF vs MCK, CAH, COR: Earnings per Share (Diluted) Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's PE Ratio falls into.
Sinopharm Group Co Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Sinopharm Group Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.32 mean?
Sinopharm Group Co (SHTDF) has a Earnings per Share (Diluted) of $0.32 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #64 out of 101 companies in the Medical Distribution industry, placing it in the top 63.4%.
Is Sinopharm Group Co's Earnings per Share (Diluted) too high?
Sinopharm Group Co's current Earnings per Share (Diluted) is $0.32. The Medical Distribution industry median Earnings per Share (Diluted) is 2.60. Sinopharm Group Co's value of $0.32 is 87.7% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #64 out of 101 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Earnings per Share (Diluted) compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #64 out of 101 companies for Earnings per Share (Diluted). This places Sinopharm Group Co in the lower half of its industry. The industry median Earnings per Share (Diluted) is 2.60. Sinopharm Group Co's value of $0.32 is 87.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Distribution company?
The median Earnings per Share (Diluted) among Medical Distribution companies is 2.60, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Earnings per Share (Diluted) of $0.32 is 87.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Earnings per Share (Diluted) is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Earnings per Share (Diluted) is $0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.58, compared to a current price of $2.13 — trading 17.3% below its estimated fair value. The current Earnings per Share (Diluted) is $0.32 and 87.7% below the Medical Distribution industry median of 2.60. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Earnings per Share (Diluted) is $0.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 17.3% below its estimated GF Value™ of $2.58.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Earnings per Share (Diluted): $0.32
GF Value™: $2.58 vs. price of $2.13 (17.3% below fair value)
Industry Position: 87.7% below the Medical Distribution median (#64 of 101)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
